Abstract: The invention relates to a method for loading and storing a vaccine composition, containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper, the surface of the device getting into contact with the composition being coated with a fluoropolymer such as Teflon™ and/or (b) loading the composition into a container wherein the inner surface of which is coated with polymerized silicone. The use of fluoropolymer or polymerized silicone optimizes the adsorbed antigen stability upon storage. In a particular embodiment, the antigen is the hepatitis B surface antigen and the aluminum adjuvant is aluminum oxy hydroxide.

Abstract: The invention relates to a method for loading and storing a vaccine composition, containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper, the surface of the device getting into contact with the composition being coated with a fluoropolymer such as Teflon™ and/or (b) loading the composition into a container wherein the inner surface of which is coated with polymerized silicone. The use of fluoropolymer or polymerized silicone optimizes the adsorbed antigen stability upon storage. In a particular embodiment, the antigen is the hepatitis B surface antigen and the aluminum adjuvant is aluminum oxy hydroxide.

Abstract: The invention relates to a method for loading and storing a vaccine composition, containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper, the surface of the device getting into contact with the composition being coated with a fluoropolymer such as Teflon™; and/or (b) loading the composition into a container wherein the inner surface of which is coated with polymerized silicone. The use of fluoropolymer or polymerized silicone optimizes the adsorbed antigen stability upon storage. In a particular embodiment, the antigen is the hepatitis B surface antigen and the aluminum adjuvant is aluminum oxy hydroxide.

Abstract: The invention relates to a method for estimating the amount of entities deposited on microparticles in suspension in a solution, and also to an associated device. The method comprises the following steps: (a) the solution is illuminated with a light source; (b) an optical signal formed by the scattering, in the solution, of the illuminating light is detected; (c) the optical signal obtained in step (b) is analyzed in order to obtain an indicator relating to this signal; (d) the indicator obtained in step (c) is compared with a reference indicator, obtained for a reference solution, the comparison making it possible to estimate the amount of entities deposited on the microparticles.

Abstract: The invention relates to a method for loading and storing a vaccine composition, containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper, the surface of the device getting into contact with the composition being coated with a fluoropolymer such as Teflon™; and/or (b) loading the composition into a container wherein the inner surface of which is coated with polymerized silicone. The use of fluoropolymer or polymerized silicone optimizes the adsorbed antigen stability upon storage. In a particular embodiment, the antigen is the hepatitis B surface antigen and the aluminum adjuvant is aluminum oxy hydroxide.

Abstract: The invention relates to a method for estimating the amount of entities deposited on microparticles in suspension in a solution, and also to an associated device. The method comprises the following steps: (a) the solution is illuminated with a light source; (b) an optical signal formed by the scattering, in the solution, of the illuminating light is detected; (c) the optical signal obtained in step (b) is analyzed in order to obtain an indicator relating to this signal; (d) the indicator obtained in step (c) is compared with a reference indicator, obtained for a reference solution, the comparison making it possible to estimate the amount of entities deposited on the microparticles.

Abstract: A method for detecting PrP in a biological human or animal sample that may contain said PrP. The method is characterized in that it uses a molecule containing at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand selected from macrocyclic ligands and glycosaminoglycans.

Abstract: The invention relates to a method for detecting PrP in a biological human or animal sample that may contain PrP. The inventive method is characterised in that it uses a molecule containing at least one positive charge and/or at least one osidic bond and a ligand other than a proteinic ligand selected from macrocyclic ligands and glycosaminoglycanes.

Abstract: The invention relates to a method for detecting PrP in a biological human or animal sample that may contain PrP. The inventive method is characterised in that it uses a molecule containing at least one positive charge and/or at least one osidic bond and a ligand other than a proteinic ligand selected from macrocyclic ligands and glycosaminoglycanes.